Extensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT

World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…

Read More

Safety and efficacy of helical tomotherapy following lung-sparing surgery in locally advanced malignant pleural mesothelioma

Strahlentherapie Und Onkologie 2023 November 22 [Link] Julian P Layer, Pascal Fischer, Cas S Dejonckheere, Gustavo R Sarria, Rebekka Mispelbaum, Sandra Tessa Hattenhauer, Shari Wiegreffe, Andrea R Glasmacher, Katharina Layer, Youness Nour, Lara Caglayan, Franziska Grau, Thomas Müdder 4, Mümtaz Köksal, Davide Scafa, Frank A Giordano, Alberto Lopez-Pastorini, Erich Stoelben, Leonard Christopher Schmeel, Christina Leitzen…

Read More

A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma

Translational Cancer Research 2023 October 31 [Link] Wei Li, Minghang Zhang, Siyu Cai, Siqi Li, Biao Yang, Shijie Zhou, Yuanming Pan, Shaofa Xu Abstract Background: Malignant pleural mesothelioma (MPM) is a rare disease with limited treatment and poor prognosis, and a precise and reliable means to predicting MPM remains lacking for clinical use. Methods: In…

Read More

Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo

Cancer Letters 2023 October 10 [Link] Karin Schelch, Dominik Emminger, Benjamin Zitta, Thomas G Johnson, Verena Kopatz, Sebastian Eder, Alexander Ries, Alessia Stefanelli, Petra Heffeter, Mir A Hoda, Konrad Hoetzenecker, Balazs Dome, Walter Berger, Glen Reid, Michael Grusch Abstract Pleural mesothelioma (PM) is characterized by poor prognosis and limited therapeutic options. Y-box-binding protein 1 (YB-1)…

Read More

Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma

Biochemical Pharmacology 2023 August [Link] Valentina Coccè, Mara Bonelli, Silvia La Monica, Roberta Alfieri, Luisa Doneda, Eleonora Martegani, Giulio Alessandri, Costanza Annamaria Lagrasta, Aldo Giannì, Valeria Sordi, Francesco Petrella, Leda Roncoroni, Francesca Paino, Augusto Pessina Abstract Malignant pleural mesothelioma is an asbestos-related tumor originating in mesothelial cells of the pleura that poorly responds to chemotherapeutic…

Read More

Targeting AXL in mesothelioma: From functional characterization to clinical implication

Critical Reviews in Oncology and Hematology 2023 June 1 [Link] Kinjal Bhadresha, Sheefa Mirza, Clement Penny, Muhammed Jameel Mughal Abstract Malignant mesothelioma (MM) is a highly aggressive and lethal cancer with a poor survival rate. Current treatment approaches primarily rely on chemotherapy and radiation, but their effectiveness is limited. Consequently, there is an urgent need…

Read More

Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma

Cancer Medicine 2023 April 19 [Link] Yang Wo, Yizhou Peng, Zhigang Wu, Pengcheng Liu, Yan Shang, Xuxia Shen, Yihua Sun Abstract Objectives: The role of postoperative radiotherapy (PORT) in malignant pleural mesothelioma (MPM) remains controversial and the eighth edition TNM staging scheme for MPM has not been fully verified. We aimed to develop an individualized…

Read More

Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database

Cancer Medicine 2023 April 16 [Link] Patrick Bou-Samra, Austin Chang, Feredun Azari, Gregory Kennedy, Alix Segil, Emily Guo, Melina Marmarelis, Corey Langer, Sunil Singhal Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer of the cells lining the pleural cavity with a low overall incidence. The National Cancer Database (NCDB) released in August 2022…

Read More

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy

International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…

Read More